Artia Global Partners LP Raises Stock Position in Ascendis Pharma A/S $ASND

Artia Global Partners LP increased its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 44.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,740 shares of the biotechnology company’s stock after purchasing an additional 5,500 shares during the quarter. Ascendis Pharma A/S accounts for 0.5% of Artia Global Partners LP’s portfolio, making the stock its 28th largest position. Artia Global Partners LP’s holdings in Ascendis Pharma A/S were worth $3,783,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Advisory Services Network LLC purchased a new stake in Ascendis Pharma A/S in the third quarter worth approximately $26,000. Arax Advisory Partners raised its position in Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG bought a new position in Ascendis Pharma A/S in the fourth quarter worth approximately $36,000. Global Retirement Partners LLC raised its position in Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares during the period. Finally, GW&K Investment Management LLC raised its position in Ascendis Pharma A/S by 75.2% in the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 97 shares during the period.

Wall Street Analyst Weigh In

ASND has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Barclays increased their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 price target on the stock. Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a research report on Wednesday, March 4th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $255.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $295.39.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at $95,120. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Stock Down 0.0%

Shares of ASND stock opened at $231.15 on Thursday. The company has a market capitalization of $14.42 billion, a price-to-earnings ratio of 26.66 and a beta of 0.39. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $250.74. The company’s fifty day moving average price is $232.16 and its 200-day moving average price is $224.09. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Sell-side analysts expect that Ascendis Pharma A/S will post 14.25 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.